MPXOF (MPX International) Notes Receivable: $0.00 Mil (As of Mar. 2022)


What is MPX International Notes Receivable?

MPX International MPXOF -99.00% Notes Receivable is $0.00 Mil as of Mar. 2022.

MPX International's Notes Receivable for the quarter that ended in Mar. 2022 was $0.00 Mil.


MPX International Notes Receivable Related Terms


MPX International Notes Receivable Historical Data

* Premium members only.

The historical data trend for MPX International's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MPX International Notes Receivable Chart

MPX International Annual Data
Trend Sep18 Sep19 Sep20 Sep21
Notes Receivable
0.00 0.00 0.00 0.00

MPX International Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MPX International Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
MPX International (MPXOF) has a Notes Receivable of $0.00 Mil as of Mar. 2022. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MPX International and its competitors.
Is MPX International's Notes Receivable too high?
MPX International's current Notes Receivable is $0.00 Mil.
How does MPX International's Notes Receivable compare to ZTS and CTLT?
MPX International's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MPX International and its competitors. MPX International's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MPX International stock overvalued right now?
MPX International (MPXOF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For MPX International (MPXOF), the current Notes Receivable is $0.00 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MPX International Business Description

Address 5255 Yonge Street, Suite 701, Toronto, ON, CAN, M2N 6P4
MPX International Corp is a diversified cannabis company focused on developing and operating assets across the global medical and adult use and engaged in cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. The firm is organized into three segments: Canada, Europe/Africa, and Asia-Pacific. The Canada operating segment's principal business activities consist of production and sale of cannabis, video learning and engagement, patient counselling and referral services. The Europe/Africa operating segment's consist of the production and sale of cannabis and hemp-related products. The Asia-Pacific consist of the production and sale of cannabis. The majority of the revenue is generated in Canada.